Coquí Pharma’s Medical Isotope Production Facility
Coquí Pharma’s Milestones
INVAP CEO and General Manager Hector E. Otheguy, Chairman of INVAP Board of Directors Horacio Osuna, and Coquí RadioPharmaceuticals Corp. President and CEO Carmen I. Bigles at the contract signing for INVAP to design Coquí Pharma’s Medical Isotope Production Facility in Alachua, Fla. (Nov. 20, 2014)
Carmen Bigles announces that Coquí Pharma has selected Alachua County as the site for new medical isotope production facility.
Coquí Radiopharmaceuticals, Corp. CEO Carmen Bigles with Comprehensive Nuclear-Test-Ban Treaty Organization Executive Secretary Lassina Zerbo in Vienna in November 2013.
Coquí Pharma meets with INVAP in Argentina.
Coquí Radiopharmaceuticals, Corp. CEO Carmen Bigles (second from left) at the Comprehensive Nuclear-Test-Ban Treaty Organization in Vienna in November 2013.” (Credit: CTBTO Preparatory Commission)
A view inside of an INVAP reactor, which is the same proven design that Coquí Pharma is planning to utilize. The blue glow is caused by the splitting of neutrons, which is ultimately responsible for the production of Mo-99, the isotope used in several lifesaving medical procedures
Another view inside of an INVAP reactor, this reactor is located in South Sydney, Australia and provides another example of what operations would look like at Coquí Pharma. Similarly, the reactor at Coquí Pharma’s facility will be a small scale research reactor (20 Mw).
Coquí Pharma partners Nedtor de Lorenzo INVAP and Robert Evans ENERCON view INVAP hot cell in Argentina.